Emerald Logic
Emerald Logic, operating as Liquid Biosciences, is a bio-analytics platform company founded around 2016 by Patrick Lilley, a serial entrepreneur with 25 years in biotech and high-performance computing.
Profile
Develops advanced bio-analytics software to accelerate drug discovery and biomarker identification.
Emerald Logic, operating as Liquid Biosciences, is a bio-analytics platform company founded around 2016 by Patrick Lilley, a serial entrepreneur with 25 years in biotech and high-performance computing. Based in Aliso Viejo, California, the company has positioned itself as a specialist in biomarker discovery and drug development acceleration, claiming over 300 projects across 60 diseases. Its client base includes 35 biopharma, diagnostic, and academic institutions.
The company emphasizes its ability to rescue failed drugs and accelerate new ones, though specific financials or funding rounds are not publicly disclosed. Liquid Biosciences operates with a small, focused team, with key executives including Lilley as CEO and Roland Muduryan as CFO/COO, both with long-standing collaborations across multiple ventures. The company's proprietary platform integrates high-performance computing and bioinformatics, with 75 patents and trade secrets cited by its leadership. What stands out now is its claim of zero project failures—a rare assertion in drug development—and its aggressive stance on speed, positioning itself against slower traditional biotech R&D cycles.
Who buys this
- Biopharmaceutical companies
- Diagnostic test developers
- Clinical research organizations
- Academic medical centers
- Hospital research divisions
Strengths and what to watch
Strengths
- Proprietary bioinformatics platform with 75 patents and trade secrets
- Track record of 300+ projects without publicized failures
- Founders with deep cross-disciplinary expertise in biotech and high-performance computing
Watch for
- Lack of disclosed financials or funding history raises questions about scalability
- Reliance on claims of 'zero failures' without independent verification
- Narrow executive team with long-standing ties could limit strategic diversity
Key Information
- Founded
- 2016
- Headquarters
- Aliso Viejo, California
Frequently Asked Questions
What is Emerald Logic?
Emerald Logic, operating as Liquid Biosciences, develops advanced bio-analytics software to accelerate drug discovery and biomarker identification. Founded in 2016, it specializes in rescuing failed drugs and speeding up new ones, with over 300 projects across 60 diseases and 75 patents.
How does Emerald Logic accelerate drug discovery?
Emerald Logic uses its proprietary bio-analytics platform to streamline drug discovery, focusing on rescuing failed drugs and accelerating new ones. The platform integrates high-performance computing and bioinformatics, claiming zero project failures and faster R&D cycles compared to traditional biotech methods.
What is biomarker identification, and how does Emerald Logic help?
Biomarker identification involves discovering measurable indicators of biological processes. Emerald Logic’s bio-analytics platform accelerates this process by analyzing complex datasets, helping biopharma and diagnostic developers identify biomarkers more efficiently for diseases, with over 300 projects completed.
Who are Emerald Logic’s clients?
Emerald Logic serves biopharmaceutical companies, diagnostic test developers, clinical research organizations, academic medical centers, and hospital research divisions. Its client base includes 35 institutions, leveraging its platform for drug discovery and biomarker identification across diverse disease areas.
What makes Emerald Logic’s platform unique?
Emerald Logic’s platform integrates high-performance computing and bioinformatics, backed by 75 patents and trade secrets. It claims zero project failures and faster R&D cycles, positioning itself as a leader in accelerating drug discovery and biomarker identification.
What are the strengths of Emerald Logic?
Emerald Logic’s strengths include its proprietary bio-analytics platform with 75 patents, a track record of 300+ projects without failures, and founders with deep expertise in biotech and high-performance computing. It focuses on accelerating drug discovery and biomarker identification for diverse clients.
Sources
- www.liquidbiosciences.com — Company overview, leadership bios, and claims about projects/patents